Cited by 1,730Renal cell carcinoma treatmentEar and Head TumorsCancer, Hypoxia, and Metabolism

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Mutations of the VHL tumour suppressor gene in renal carcinoma

Gnarra, J.R., Tory, K., Weng, Y., Schmidt, L., Wei, M.H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., Lubensky, I., Duan, D.R., Florence, C., Pozzatti, R., Walther, M. M., Bander, N.H., Grossman, H.B., Brauch, H., Pomer, S., Brooks, J.D., Isaacs, W.B., Lerman, M.I., Zbar, B., Linehan, W.M.·1994·Nature Genetics

DOI 10.1038/ng0594-85

Open this paper in CoChat — free account

Abstract

Multiple, bilateral renal carcinomas are a frequent occurrence in von Hippel-Lindau (VHL) disease. To elucidate the aetiological role of the VHL gene in human kidney tumorigenesis, localized and advanced tumours from 110 patients with sporadic renal carcinoma were analysed for VHL mutations and loss of heterozygosity (LOH). VHL mutations were identified in 57% of clear cell renal carcinomas analysed and LOH was observed in 98% of those samples. Moreover, VHL was mutated and lost in a renal tumour from a patient with familial renal carcinoma carrying the constitutional translocation, t(3;8)(p14;q24). The identification of VHL mutations in a majority of localized and advanced sporadic renal carcinomas and in a second form of hereditary renal carcinoma indicates that the VHL gene plays a critical part in the origin of this malignancy.

Integrity signals

Registry

Crossref · 10.1038/ng0594-85

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J. R., Yao, M., Duh, F.-M. C., Orcutt, M. L., Stackhouse, T. M., Kuzmin, I., Modi, W. S., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,971
Self-citation
The Results of Radical Nephrectomy for Renal Cell Carcinoma
Robson, C. J., Churchill, B. M., & Anderson, W. D. (1969) · The Journal of Urology · doi:10.1016/s0022-5347(17)62331-0 · Cited by 1,303
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P. J., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,298
Hereditary cancer, oncogenes, and antioncogenes.
Knudson, A. G. (1985) · PubMed · Cited by 1,218
The Results of Radical Nephrectomy for Renal Cell Carcinoma
Robson, C. J., Churchill, B. M., & Anderson, W. D. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.10.095 · Cited by 1,160
A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Höppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,143
Diseases of the kidney
Strauss, M. B., & Welt, L. G. (1963) · Little, Brown eBooks · Cited by 823
Mutations of the RET proto-oncogene in Hirschsprung's disease
Edery, P., Lyonnet, S., Mulligan, L. M., Pelet, A., Dow, E., Abel, L., Holder, S., Nihoul‐Feketé, C., Ponder, B. A. J., & Münnich, A. (1994) · Nature · doi:10.1038/367378a0 · Cited by 746
Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease
Romeo, G., Ronchetto, P., Luo, Y., Barone, V., Seri, M., Ceccherini, I., Pasini, B., Bocciardi, R., Lerone, M., Kääriäinen, H., et al. (1994) · Nature · doi:10.1038/367377a0 · Cited by 698
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC
Mulligan, L. M., Eng, C., Healey, C. S., Clayton, D. G., Kwok, J. B., Gardner, E., Ponder, M. A., Frilling, A., Jackson, C. E., Lehnert, H., et al. (1994) · Nature Genetics · doi:10.1038/ng0194-70 · Cited by 643

Flagged first, then by citations

Show all 29 references

Research works printed but not linked: 1

Glenn, G.M., Choyke, P.L., Zbar, B. & Linehan, W.M. von Hippel-Lindau disease: clinical review and molecular genetics. Problems Urol. 4, 312–330 (1990).

Sorted by citations

Items 701–800 of 1,002

Molecular analysis of a familial case of renal cell cancer and a t(3;6)(q12;q15)
Eleveld, M. J., Bodmer, D., Merkx, G. F. M., Siepman, A., Sprenger, S. H. E., Weterman, M. A. J., Ligtenberg, M. J. L., van de Kamp, J., Stapper, W., Jeuken, J. W. M., et al. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1114 · Cited by 37
Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter
Zatyka, M., Morrissey, C., Kuzmin, I., Lerman, M. I., Latif, F., Richards, F. M., & Maher, E. R. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.7.463 · Cited by 37
Self-citation
Equitable access to cancer services
Mandelblatt, J. S., Yabroff, K. R., & Kerner, J. F. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991201)86:11 · Cited by 269
Selection of Mutant CHO Cells with Constitutive Activation of the HIF System and Inactivation of the von Hippel-Lindau Tumor Suppressor
Vaux, E. C., Wood, S. M., Cockman, M. E., Nicholls, L. G., Yeates, K. M., Pugh, C. W., Maxwell, P. H., & Ratcliffe, P. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104678200 · Cited by 37
A small-molecule VHL molecular glue degrader for cysteine dioxygenase 1
Tutter, A., Buckley, D., Golosov, A. A., Ma, X., Shu, W., McKay, D. J. J., Darsigny, V., Dovala, D., Beckwith, R., Solomon, J., et al. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01936-x · Cited by 36
Deubiquitylase OTUD6B stabilizes the mutated pVHL and suppresses cell migration in clear cell renal cell carcinoma
Guo, K., Wei, Y., Wang, Z., Zhang, X., Zhang, X., Liu, X., Wu, W., Wu, Z., Zhang, L., & Cui, C. (2022) · Cell Death and Disease · doi:10.1038/s41419-021-04135-3 · Cited by 36
Sunitinib in the Treatment of Advanced Solid Tumors
Imbulgoda, A., Heng, D. Y. C., & Kollmannsberger, C. (2014) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-54490-3_9 · Cited by 37
Molecular mechanisms underlying the MiT translocation subgroup of renal cell carcinomas
Medendorp, K., van Groningen, J. J. M., Schepens, M. T., Vreede, L., Thijssen, J. A. G. M., Schoenmakers, E., van den Hurk, H., van Kessel, A. G., & Kuiper, R. P. (2007) · Cytogenetic and Genome Research · doi:10.1159/000108296 · Cited by 37
The Elongin BC complex and the von Hippel–Lindau tumor suppressor protein
Conaway, J. W., Kamura, T., & Conaway, R. C. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00035-8 · Cited by 36
pVHL-independent ubiquitination of HIF1α and its stabilization by cobalt ion
Kanaya, K., & Kamitani, T. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01041-6 · Cited by 36
von Hippel-Lindau Gene Mutations in N-Nitrosodimethylamine-Induced Rat Renal Epithelial Tumors
Shiao, Y., Anderson, L. M., Diwan, B. A., Rice, J. M., & Hard, G. C. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.22.1720 · Cited by 36
Molecular biology of lung cancer
Sozzi, G. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)80008-3 · Cited by 36
Renal cell carcinoma
Zhao, W. P., Gnarra, J. R., Liu, S., Knutsen, T., Linehan, W. M., & Whang‐Peng, J. (1995) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(95)00024-j · Cited by 36
Self-citation
FOXO1 and TCF7L2 genes involved in metastasis and poor prognosis in clear cell renal cell carcinoma
Kojima, T., Shimazui, T., Horie, R., Hinotsu, S., Oikawa, T., Kawai, K., Suzuki, H., Meno, K., Akaza, H., & Uchida, K. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20750 · Cited by 35
Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype
Kammerer‐Jacquet, S., Brunot, A., Pladys, A., Bouzillé, G., Dagher, J., Médane, S., Peyronnet, B., Mathiéu, R., Verhoest, G., Bensalah, K., et al. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.06.007 · Cited by 35
Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma
Lindner, A. K., Tulchiner, G. A., Seeber, A., Siska, P. J., Thurnher, M., & Pichler, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.906014 · Cited by 38
Nucleostemin mRNA is expressed in both normal and malignant renal tissues
Fan, Y., Liu, Z., Zhao, S., Lou, F., Nilsson, S. F., Ekman, P., Xu, D., & Fang, X. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603145 · Cited by 35
The genetics of renal tumors in end-stage renal failure differs from those occurring in the general population.
Chudek, J. T., Herbers, J., Wilhelm, M., Kenck, C., Bugert, P., Ritz, E., Waldman, F., & Kovács, G. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v961045 · Cited by 35
The genetic basis of renal epithelial tumors: advances in research and its impact on prognosis and therapy
Phillips, J. L., Pavlovich, C. P., Walther, M. M., Ried, T., & Linehan, W. M. (2001) · Current Opinion in Urology · doi:10.1097/00042307-200109000-00003 · Cited by 35
Self-citation
A Recombinant Adenovirus Expressing P27(KIP1) Induces Cell Cycle Arrest and Apoptosis In Human 786???0 Renal Carcinoma Cells
Katner, A., Gootam, P., Hoang, Q. B. L., Gnarra, J. R., & Rayford, W. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64742-8 · Cited by 35
Self-citation
Molecular Genetics of Renal Cell Carcinoma
Enquist, E. G., Zambrano, N., Zbar, B., Linehan, W. M., & Walther, M. M. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-229-6_5 · Cited by 35
Self-citation
Editorial: Molecular Targeting of VHL Gene Pathway in Clear Cell Kidney Cancer
Linehan, W. M. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000077210.05543.ae · Cited by 35
Self-citation
Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling
Matsumura, N., Mandai, M., Okamoto, T., Yamaguchi, K. D., Yamamura, S., Oura, T., Baba, T., Hamanishi, J., Kang, H., Matsui, S., et al. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01736.x · Cited by 34
Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields
Martín‐Sánchez, D., Fontecha‐Barriuso, M., Sánchez-Niño, M. D., Ramos, A. M., Benavente, R. C., Enguita, C. G., Linkermann, A., Sanz, A. B., & Ortíz, A. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0043-2 · Cited by 35
The role of endothelial colony forming cells in kidney cancer’s pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review
Poletto, V., Rosti, V., Biggiogera, M., Guerra, G., Moccia, F. D., & Porta, C. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.09.005 · Cited by 34
Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment
Garje, R., An, J., Sanchez, K. G., Greco, A., Stolwijk, J. M., Devor, E. J., Rustum, Y. M., & Zakharia, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123834 · Cited by 34
Impairment of Plasmacytoid Dendritic Cells for IFN Production by the Ligand for Immunoglobulin-Like Transcript 7 Expressed on Human Cancer Cells
Tsukamoto, N., Okada, S., Onami, Y., Sasaki, Y., Umezawa, K., & Kawakami, Y. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0171 · Cited by 34
Relevance of Nuclear and Cytoplasmic von Hippel Lindau Protein Expression for Renal Carcinoma Progression
Schraml, P., Hergovitz, A., Hatz, F., Amin, M. B., Lim, S. D., Krek, W., Mihatsch, M. J., & Moch, H. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63461-x · Cited by 34
A constitutional balanced t(3;8)(p14;q24.1) translocation results in disruption of the TRC8 gene and predisposition to clear cell renal cell carcinoma
Poland, K. S., Azim, M. F., Folsom, M. R., Goldfarb, R. A., Naeem, R., Korch, C. T., Drabkin, H. A., Gemmill, R. M., & Plon, S. E. (2007) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20466 · Cited by 34
Determination of vhl Gene Mutations in Sporadic Renal Cell Carcinoma
Bachs, J. M. G., Sánchez, A. S. S., Sánchez‐Sánchez, F., Lorenzo‐Romero, J. G., Donate‐Moreno, M. J., Pastor‐Navarro, H., Garcı́a-Olmo, D. C., Escribano, J., & Virseda‐Rodriguez, J. A. (2005) · European Urology · doi:10.1016/j.eururo.2005.10.028 · Cited by 34
Molecularly targeted therapy in renal cell carcinoma
Rathmell, W. K., Wright, T. M., & Rini, B. I. (2005) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.5.6.1031 · Cited by 34
Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma
Gill, D. M., Agarwal, N., & Vaishampayan, U. N. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_174469 · Cited by 34
Expression of CXCR3 on Mononuclear Cells and CXCR3 Ligands in Patients With Metastatic Renal Cell Carcinoma in Response to Systemic IL-2 Therapy
Reckamp, K. L., Figlin, R. A., Moldawer, N. P., Pantuck, A. J., Belldegrun, A. S., Burdick, M. D., & Strieter, R. M. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31802e089a · Cited by 34
Von Hippel-Lindau tumor suppressor protein transforms human neuroblastoma cells into functional neuron-like cells.
Murata, H., Tajima, N., Nagashima, Y., Yao, M., Baba, M., Goto, M., Kawamoto, S., Yamamoto, I., Okuda, K., & Kanno, H. (2002) · PubMed · Cited by 34
Hypertension, antihypertensives and mutations in the Von Hippel–Lindau gene in renal cell carcinoma: results from the Netherlands Cohort Study
Schouten, L. J., van Dijk, B. A. C., Oosterwijk, E., de Kaa, C. A. H., Kiemeney, L. A. L. M., Goldbohm, R. A., Schalken, J. A., & van den Brandt, P. A. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000186023.74245.48 · Cited by 34
Somatic Mutation of the Tuberous Sclerosis (Tsc2) Tumor Suppressor Gene in Chemically Induced Rat Renal Carcinoma Cell
Urakami, S., Tokuzen, R., Tsuda, H., Igawa, M., & Hino, O. (1997) · The Journal of Urology · doi:10.1097/00005392-199707000-00085 · Cited by 34
Clinical and Molecular Prognostic Factors in Renal Cell Carcinoma: What We Know So Far
Tang, P. A., Vickers, M. M., & Heng, D. Y. C. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.04.003 · Cited by 33
Recent advances in the biology of tumour hypoxia with relevance to diagnostic practice and tissue‐based research
Macklin, P. S., Yamamoto, A., Browning, L., Hofer, M., Adam, J., & Pugh, C. W. (2020) · The Journal of Pathology · doi:10.1002/path.5402 · Cited by 33
Analysis of von Hippel—Lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity
Gijtenbeek, J. M. M., Jacobs, B., Sprenger, S. H. E., Eleveld, M. J., van Kessel, A. G., Kros, J. M., Sciot, R., Calenbergh, F. V., Wesseling, P., & Jeuken, J. W. M. (2002) · Journal of neurosurgery · doi:10.3171/jns.2002.97.4.0977 · Cited by 33
Parathyroid hormone-related protein induces cell survival in human renal cell carcinoma through the PI3K Akt pathway: evidence for a critical role for integrin-linked kinase and nuclear factor kappa B
Agouni, A., Sourbier, C., Danilin, S., Rothhut, S., Lindner, V., Didier Jacqmin, D., Helwig, J., Lang, H., & Massfelder, T. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm106 · Cited by 33
Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs
Jackson, R. A., & Chen, E. S. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.014 · Cited by 33
Wild-type VHL Clear Cell Renal Cell Carcinomas Are a Distinct Clinical and Histologic Entity: A 10-Year Follow-up
Dagher, J., Kammerer‐Jacquet, S., Brunot, A., Pladys, A., Patard, J., Bensalah, K., Perrin, C., Verhoest, G., Mosser, J., Lespagnol, A., et al. (2015) · European Urology Focus · doi:10.1016/j.euf.2015.06.001 · Cited by 33
Vitamin A and cancer prevention I: Observations in workers previously exposed to asbestos at Wittenoom, Western Australia
Musk, A. W., de Klerk, N. H., Ambrosini, G. L., Eccles, J. L., Hansen, J., Olsen, N. J., Watts, V. L., Lund, H., Pang, S., Beilby, J. P., et al. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980130)75:3 · Cited by 77
Rapid Mutation Scanning of Genes Associated with Familial Cancer Syndromes Using Denaturing High-Performance Liquid Chromatography
Marsh, D. J., Theodosopoulos, G., Howell, V. M., Richardson, A., Benn, D. E., Proos, A., Eng, C., & Robinson, B. G. (2001) · Neoplasia · doi:10.1038/sj.neo.7900154 · Cited by 33
von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology
Shirole, N. H., & Kaelin, W. G. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.04.011 · Cited by 34
Trichloroethylene exposure and somatic mutations of the VHL gene in patients with Renal Cell Carcinoma
Charbotel, B., Gad, S., Caïola, D., Béroud, C., Févotte, J., Bergeret, A., Ferlicot, S., & Richard, S. (2007) · Journal of Occupational Medicine and Toxicology · doi:10.1186/1745-6673-2-13 · Cited by 32
Identification of genes associated with renal cell carcinoma using gene expression profiling analysis
Yao, T. S., Wang, Q., Zhang, W., AiHong, B., & Zhang, J. (2016) · Oncology Letters · doi:10.3892/ol.2016.4573 · Cited by 32
Detecting circulating tumor DNA in renal cancer: An open challenge
Corrò, C., Hejhal, T., Poyet, C., Sulser, T., Hermanns, T., Winder, T. L., Prager, G. W., Wild, P. J., Frew, I. J., Moch, H., et al. (2017) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2017.02.009 · Cited by 32
Ubiquitination of MAP1LC3B by pVHL is associated with autophagy and cell death in renal cell carcinoma
Kang, H. M., Noh, K. H., Chang, T. K., Park, D., Cho, H., Lim, J. H., & Jung, C. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1520-6 · Cited by 33
Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression
Shi, H., Sun, Y., He, M., Yang, X. W., Hamada, M., Fukunaga, T., Zhang, X., & Chang, C. (2019) · Oncogene · doi:10.1038/s41388-019-0962-8 · Cited by 32
An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications
Choueiri, T. K., Baz, R., McFadden, C. M., Khasawneh, M. K., Karam, M. A., Kelly, M., & Hussein, M. A. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07268.x · Cited by 32
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET
Négrier, S., Jäger, E., Porta, C., McDermott, D. F., Moore, M. J., Joaquim Bellmunt, B., Anderson, S. E., Cihon, F., Lewis, J. M., Escudier, B. J., et al. (2009) · Medical Oncology · doi:10.1007/s12032-009-9303-z · Cited by 32
Safety and tolerability of pazopanib in the treatment of renal cell carcinoma
Zivi, A., Cerbone, L., Recine, F., & Sternberg, C. N. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.712108 · Cited by 32
Everolimus – a new approach in the treatment of renal cell carcinoma
Eisen, T. G. (2010) · Cancer Management and Research · doi:10.2147/cmar.s6047 · Cited by 32
Targeting the Loss of the von Hippel-Lindau Tumor Suppressor Gene in Renal Cell Carcinoma Cells
Sutphin, P. D., Chan, D. A., Li, J. M., Turcotte, S., Krieg, A. J., & Giaccia, A. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0604 · Cited by 32
Association of GSTT1 non-null and NAT1 slow/rapid genotypes with von Hippel-Lindau tumour suppressor gene transversions in sporadic renal cell carcinoma
Gallou‐Kabani, C., Longuemaux, S., Deloménie, C., Méjean, A., Martin, N., Martinet, S., Palais, G., Bouvier, R., Droz, D., Krishnamoorthy, R., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200108000-00007 · Cited by 32
Endolymphatic sac tumors in patients with and without von Hippel—Lindau disease: the role of genetic mutation, von Hippel—Lindau protein, and hypoxia inducible factor-1α expression
Jensen, R. L., Gillespie, D. L., House, P. A., Layfield, L. J., & Shelton, C. (2004) · Journal of neurosurgery · doi:10.3171/jns.2004.100.3.0488 · Cited by 32
Mutation of von Hippel–Lindau tumor suppressor gene in a sporadic endolymphatic sac tumor
Hamazaki, S., Yoshida, M., Yao, M., Nagashima, Y., Taguchi, K., Nakashima, H., & Okada, S. (2001) · Human Pathology · doi:10.1053/hupa.2001.28961 · Cited by 32
Surgical pathology of renal epithelial neoplasms: recent advances and current status
Fleming, F., & O'Donnell (2000) · Histopathology · doi:10.1046/j.1365-2559.2000.00839.x · Cited by 32
Detailed microsatellite analysis of chromosome 3p region in non-papillary renal cell carcinomas
Chudek, J. T., Wilhelm, M., Bugert, P., Herbers, J., & Kovács, G. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971009)73:2 · Cited by 32
Mutations of the von Hippel–Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma
Perier, A., Fregni, G., Wittnebel, S., Gad, S., Allard, M., Gervois, N., Escudier, B. J., Azzarone, B. G., & Caignard, A. (2011) · Oncogene · doi:10.1038/onc.2010.638 · Cited by 31
Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2α Inhibitor PT2385 In Vivo and In Vitro
Xie, C., Gao, X., Sun, D., Zhang, Y.-B., Krausz, K. W., Qin, X., & Gonzalez, F. J. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.079723 · Cited by 34
Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status
Sitaram, R. T., Landström, M., Roos, G., & Ljungberg, B. (2020) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2020-206693 · Cited by 31
Regulation of receptor for activated C kinase 1 protein by the von Hippel–Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness
He, X., Wang, J., Messing, E. M., & Wu, G. (2010) · Oncogene · doi:10.1038/onc.2010.427 · Cited by 31
Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110
Kim, H. L., Sun, X., Subjeck, J. R., & Wang, X. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0258-z · Cited by 31
Downregulation of dystroglycan glycosyltransferases LARGE2 and ISPD associate with increased mortality in clear cell renal cell carcinoma
Miller, M. R., Ma, D., Schappet, J., Breheny, P. J., Mott, S. L., Bannick, N., Askeland, E. J., Brown, J. A., & Henry, M. D. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0416-z · Cited by 31
High frequency of novel germline mutations in the VHL gene in the heterogeneous population of Brazil: Table 1
da Rocha, J. C. C., Silva, R. L. A., Mendonca, B. B., Marui, S., Simpson, A. J. G., & Camargo, A. A. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.3.e31 · Cited by 31
Recent developments in small molecule therapies for renal cell carcinoma
Song, M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.007 · Cited by 31
How many pathways to pheochromocytoma?
Neumann, H. P. H., Hoegerle, S., Manz, T., BRENNER, K. R., & Iliopoulos, O. (2002) · Seminars in Nephrology · doi:10.1053/snep.2002.30207 · Cited by 31
Molecular Genetics of Renal Carcinogenesis
Walker, C. L. (1998) · Toxicologic Pathology · doi:10.1177/019262339802600113 · Cited by 31
Role of the ubiquitin proteasome system in renal cell carcinoma
Corn, P. G. (2007) · BMC Biochemistry · doi:10.1186/1471-2091-8-s1-s4 · Cited by 34
A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance
Akaza, H., Oya, M., Iijima, M., Hyodo, I., Gemma, A., Itoh, H., Adachi, M., Okayama, Y., Sunaya, T., & Inuyama, L. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv099 · Cited by 30
Resistance to angiogenesis inhibitors in renal cell carcinoma.
Tamaskar, I., Dhillon, J., & Пили, Р. (2011) · PubMed · Cited by 30
Compromised JMJD6 Histone Demethylase Activity Affects VHL Gene Repression in Preeclampsia
Alahari, S., Post, M., Rolfo, A., Weksberg, R., & Caniggia, I. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02197 · Cited by 31
VHL-Mediated Regulation of CHCHD4 and Mitochondrial Function
Briston, T., Stephen, J. M., Thomas, L. W., Esposito, C., Chung, Y.-L., Syafruddin, S. E., Turmaine, M., Maddalena, L. A., Greef, B., Szabadkai, G., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00388 · Cited by 31
The entire miR‐200 seed family is strongly deregulated in clear cell renal cell cancer compared to the proximal tubular epithelial cells of the kidney
Duns, G., van den Berg, A., van Dijk, M. C. R. F., van Duivenbode, I., Giezen, C., Kluiver, J. L., van Goor, H., Hofstra, R. M. W., van den Berg, E., & Kok, K. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22016 · Cited by 30
TCF 21 hypermethylation regulates renal tumor cell clonogenic proliferation and migration
Gooskens, S. L. M., Klasson, T. D., Gremmels, H., Logister, I., Pieters, R., Perlman, E. J., Giles, R. H., & van den Heuvel‐Eibrink, M. M. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12149 · Cited by 30
IGF-I and IGFBP-3 augment transforming growth factor-β actions in human renal carcinoma cells
Rosendahl, A., & Forsberg, G. (2006) · Kidney International · doi:10.1038/sj.ki.5001805 · Cited by 30
The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIMEL
Guo, Y., Schoell, M. C., & Freeman, R. S. (2009) · Oncogene · doi:10.1038/onc.2009.35 · Cited by 30
Mutation of the von Hippel‐Lindau (VHL) gene in human colorectal carcinoma: Association with cytoplasmic accumulation of hypoxia‐inducible factor (HIF)‐1α
Kuwai, T., Kitadai, Y., Tanaka, S., Hiyama, T., Tanimoto, K., & Chayama, K. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03196.x · Cited by 30
Molecular Cytogenetic Analysis of 17 Renal Cancer Cell Lines: Increased Copy Number at 5q31‐33 in Cell Lines from Nonpapillary Carcinomas
Yang, Z.-Q., Yoshida, M. A., Fukuda, Y., Kurihara, N., Nakamura, Y., & Inazawa, J. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb00927.x · Cited by 30
The prolyl hydroxylase enzymes that act as oxygen sensors regulating destruction of hypoxia-inducible factor α
Willam, C., Nicholls, L. G., Ratcliffe, P. J., Pugh, C. W., & Maxwell, P. H. (2004) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2003.11.017 · Cited by 31
p53 expression and risk factors for cutaneous melanoma: A case-control study
Whiteman, D. C., Parsons, P. G., & Green, A. C. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980911)77:6 · Cited by 154
Solution structure and dynamics of yeast elongin C in complex with a von hippel-lindau peptide 1 1Edited by M. F. Summers
Botuyan, M. V., Mer, G., Yi, G.-S., Koth, C. M., Case, D. A., Edwards, A. M., Chazin, W., & Arrowsmith, C. H. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4938 · Cited by 30
The interactome of CCT complex—a computational analysis
Narayanan, A., Pullepu, D., & Kabir, M. A. (2016) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2016.09.002 · Cited by 29
ZBRK1, a novel tumor suppressor, activates VHL gene transcription through formation of a complex with VHL and p300 in renal cancer
Chen, K., Gan, Y., Gumireddy, K., Li, A., Yao, W., Gao, L., Chen, S., Hao, J., Wang, J., Huang, Q., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3134 · Cited by 29
Extraneural hemangioblastoma of the kidney: the challenge for clinicopathological diagnosis
Wu, Y., Wang, T., Zhang, P.-P., Yang, X., Wang, J., & Wang, C. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-202900 · Cited by 29
Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes
Büscheck, F., Fraune, C., Simon, R., Kluth, M., Hube‐Magg, C., Möller‐Koop, C., Sarper, I., Ketterer, K., Henke, T. L. C., Eichelberg, C., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27428 · Cited by 29
Clear-Cell and Papillary Carcinoma of the Kidney
Hughson, M. D., Dickman, K. G., Bigler, S. A., Meloni, A. M., & Sandberg, A. A. (1998) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(98)00068-5 · Cited by 29
Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes
Bangiyeva, V., Rosenbloom, A., Alexander, A. E., Isanova, B., Popko, T., & Schoenfeld, A. R. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-229 · Cited by 29
Primary Capillary Hemangioblastoma of Peripheral Soft Tissues
Michal, M., Vaněček, T., Šíma, R., Mukenšnábl, P., Boudová, L., Brouckova, M., & Koudepa, K. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200407000-00018 · Cited by 29
Allelic Deletion of VHL Gene Detected in Papillary Tumors of the Broad Ligament, Epididymis, and Retroperitoneum in von Hippel-Lindau Disease Patients
Shen, T., Zhuang, Z., Dj, G., & Tavassoli, F. A. (2000) · International Journal of Surgical Pathology · doi:10.1177/106689690000800308 · Cited by 29
Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma
Parker, A. S., Cheville, J. C., Lohse, C. M., Igel, T. C., Leibovich, B. C., & Blute, M. L. (2005) · Urology · doi:10.1016/j.urology.2004.12.040 · Cited by 29
Mutations in the von Hippel‐Lindau (VHL) gene refine differential diagnostic criteria in renal cell carcinoma
Barnabas, N., Amin, M., Pindolia, K. R., Nanavati, R., Amin, M. B., & Worsham, M. J. (2002) · Journal of Surgical Oncology · doi:10.1002/jso.10086 · Cited by 29
Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin
Lin, J., Chen, Y., Huang, Y.-T., & Lin‐Shiau, S. (1997) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(1997)28/29+ · Cited by 163
Evidence for aldosterone‐dependent growth of renal cell carcinoma
King, S., Bray, S. E., Galbraith, S., Christie, L., & Fleming, S. (2014) · International Journal of Experimental Pathology · doi:10.1111/iep.12074 · Cited by 28
Mining genome sequencing data to identify the genomic features linked to breast cancer histopathology
Ping, Z., Siegal, G. P., Almeida, J. S., Schnitt, S. J., & Shen, D. (2014) · Journal of Pathology Informatics · doi:10.4103/2153-3539.126147 · Cited by 28
Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity
Fisher, R. A., Larkin, J., & Swanton, C. (2011) · The EPMA Journal · doi:10.1007/s13167-011-0137-3 · Cited by 28
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma
Voss, M. H., Bhatt, R. S., Plimack, E. R., Rini, B. I., Alter, R. S., Beck, J. T., Wilson, D. M., Zhang, X., Mutyaba, M., Glasser, C. E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2395 · Cited by 28
RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition
Earwaker, P., Anderson, C. J., Willenbrock, F. W., Harris, A. L., Protheroe, A. S., & Macaulay, V. M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191890 · Cited by 28

Authors: Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., Lubensky, I., Duan, D. R., Florence, C., Pozzatti, R., Walther, M. M., Bander, N. H., Grossman, H. B., Brauch, H., Pomer, S., Brooks, J. D., Isaacs, W. B., Lerman, M. I., Zbar, B., & Linehan, W. M.
Affiliations: National Cancer Institute (US)
Frederick National Laboratory for Cancer Research (US)
National Institutes of Health (US)
Cornell University (US)
University of Michigan (US)
Technical University of Munich (DE)
Heidelberg University (DE)
Johns Hopkins University (US)
ORCID: Gnarra, J.R.
Schmidt, L.
Wei, M.H.
Lubensky, I.
Bander, N.H.
Brauch, H.
Brooks, J.D.
Isaacs, W.B.
Lerman, M.I.
Linehan, W.M.
Venue: Nature Genetics
Publisher: Springer Science and Business Media LLC
Published: 1994-05
Volume: 7
Issue: 1
Pages: 85-90
ISSN: 1061-4036 (ISSN-L)
1546-1718
DOI: 10.1038/ng0594-85
OpenAlex: W2010160635
Cited by: 1,730
References: 29
Citations by year: 2026: 17 · 2025: 25 · 2024: 30 · 2023: 38 · 2022: 38 · 2021: 45 · 2020: 56 · 2019: 47 · 2018: 45 · 2017: 42 · 2016: 57 · 2015: 35 · 2014: 70 · 2013: 66 · 2012: 62
FWCI: 61.77
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Genetics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Health Sciences › Medicine › Oncology › Ear and Head Tumors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords: VHL gene, von Hippel-Lindau disease, renal carcinoma, clear cell renal cell carcinoma, loss of heterozygosity
MeSH terms: Base Sequence, Carcinoma, DNA Mutational Analysis, DNA, Neoplasm, von Hippel-Lindau Disease, Humans, Kidney Neoplasms, Molecular Sequence Data, Mutation, Organ Specificity, Polymorphism, Restriction Fragment Length, Genes, Tumor Suppressor, Neoplasms, Second Primary, Sequence Deletion, Adenocarcinoma, Clear Cell

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mutations of the VHL tumour suppressor gene in renal carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks